Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Sep;11(3):110-6.
doi: 10.4103/1450-1147.103409.

Standard Operating Procedure for Prospective Individualised Dosimetry for ([131])I-rituximab Radioimmunotherapy of Non-Hodgkin's Lymphoma

Phillipe J Calais  1 , J Harvey Turner
Affiliations

Standard Operating Procedure for Prospective Individualised Dosimetry for ([131])I-rituximab Radioimmunotherapy of Non-Hodgkin's Lymphoma

Phillipe J Calais et al. World J Nucl Med. 2012 Sep.

Abstract

Radioimmunotherapy (RIT) is an attractive therapy for non-Hodgkin's lymphoma (NHL) as it allows targeted tumor irradiation which provides a cytotoxic effect significantly greater than that of the immune-mediated effects of a non-radioactive, or 'cold', antibody alone. Anti-CD20 antibodies such as rituximab are ideal for RIT, as not only is it easily iodinated, but the CD20 antigen is found on more than 95% of B-cell NHL. A standard operating procedure (SOP) has been formulated for personalized prospective dosimetry for safe, effective outpatient (131)I-rituximab RIT of NHL. Over five years, experience of treatment of outpatients with (131)I-rituximab was analyzed with respect to critical organ radiation dose in patients and radiation exposure of their carers. This radiation safety methodology has been refined; and offers the potential for safe, practical application to outpatient (131)I-rituximab RIT of lymphoma in general and in developing countries in particular. Given endorsement and sanction of this SOP by local regulatory authorities the personalized dosimetry paradigm will facilitate incorporation of RIT into the routine clinical practice of therapeutic nuclear oncology worldwide.

Keywords: Dosimetry; I-131 rituximab; non-Hodgkin's lymphoma; standard operating procedure.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared

Figures

Figure 1
Figure 1
Total whole body residence time estimation
Figure 2
Figure 2
Total whole body residence time calculation
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Calais PJ, Turner JH. Outpatient 131 I-Rituximab Radioimmunotherapy for non-Hodgkin's lymphoma: A study in safety. Clin Nucl Med. 2012;37:732–7. - PubMed
    1. Leahy MF, Turner JH. Radioimmunotherapy of relapsed indolent non-Hodgkin's lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients. Blood. 2011;117:45–52. - PubMed
    1. Pickford MD, Turner JH. Standard operating procedure for Iodine-131-rituximab preparation, quality control, and dispensing in Radio-pharmaceutical Laboratories in Hospital Departments of Nuclear Medicine2012;11:In this issue? World J Nucl Med. 2012;11:105–9. - PubMed
    1. Turner JH, Martindale AA, Boucek J, Claringbold PG, Leahy MF. 131I-Anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkin's lymphoma: A phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital. Cancer Biother Radiopharm. 2003;18:513–24. - PubMed
    1. Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte-specific antigen. J Immunol. 1980;125:1678–85. - PubMed